LOCOA® (Esflurbiprofen), a transdermal patch, developed to help osteoarthritis patients relieve pain that affects their daily movements and activities.

Osteoarthritis is a common joint disease and is one of the largest contributors to global disability. When a person is diagnosed with osteoarthritis, it is likely that pain will appear more often, so early preventive measures should be taken even if there is no cure for the disease, but we can see the level of treatment has improved in recent years and benefits have been gained when starting treatment at an early stage.

LOCOA® produced in Japan has been approved since 2016 aimed at providing a variety of options to osteoarthritis patients in reducing pain more effectively.

The disease is most common in men before the age of 45 and women after the age of 45. Among the common symptoms experienced by osteoarthritis patients include joint pain, joint spasm, swelling, loss of function, changes in joint appearance, decreased joint strength, knee tingling or pain when around the joint is pressed.